MedTrace Logo

A Unique Regimen for Treatment of Helicobacter Pylori Infection

NCT03491995 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2018-04-10

No results posted yet for this study

Summary

The triple treatment including Proton pump inhibitor (PPI) -clarithromycin and amoxicillin or metronidazole was proposed 30 years ago at the first Maastricht conference to treat helicobacter pylori (H. pylori) infection and since that time, it has become the universal and standard treatment for helicobacter pylori.

However, the efficacy of this triple regimen has been seriously challenged, and they are gradually becoming ineffective

Conditions

  • Helicobacter Infections

Interventions

DRUG

Quadruple therapy

Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin

DRUG

Classic treatment

Omeprazole, amoxycillin, clarithromycin

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Ayman Yousry, Prof · Head of Hepatology and infectious diseases dept.-Cairo University

  • Walied El-Hossary, MD · Hepatology and infectious diseases dept.-Cairo University

  • Mohamed Alboraie, MD · Internal Medicine dept.-Alazhar University

  • Sherief Abd-Elsalam, MD · Hepatology and Infectious diseases- Tanta University

  • Asem Elfert, Prof · Hepatology and Infectious diseases- Tanta University

  • Hussein A Elamin, Prof · Internal Medicine-Assuit University

  • Mohamed Adel Elbasiony, MD · Internal Medicine- Mansoura University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2023-04-01
Completion
2023-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03491995 on ClinicalTrials.gov